Navigation Links
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Date:2/15/2008

NEW HAVEN, Conn., Feb. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that the Company had paid interest due February 15, 2008 on its 7.75% Convertible Senior Notes due 2012 (the "Notes"). The aggregate principal amount of the Notes is $60 million.

The Company paid $2,376,666.67 through the issuance of shares of its registered Common Stock. Approximately $2,376,345.60 was paid in 5,500,800 shares of Common Stock, based on today's closing bid price of $0.432, which is approximately equal to 91.68 shares of Common Stock per each $1,000 principal amount of Notes. Cash interest was paid in lieu of fractional shares.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Announces Additions to Management Team
2. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
3. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
4. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. Vion Pharmaceuticals Holds Special Meeting of Stockholders
7. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
8. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ire/ - Cytochroma today announced the appointment ... Moldt will replace Mr. Ulrik Spork as the Novo A/...r of Board members remains unchanged at six member...dt to the board and look forward to benefiting fro...ues to make progress in becoming a leading CKD-foc...
(Date:11/24/2009)...ire-FirstCall/ -- IES (Nasdaq: IESC ), a leading ... systems and services for the commercial, industri...ts commercial business group has been awarded a co...ctrical systems for the Level 4 bio-safety lab (BS... Research Institute of Infectious Diseases (USAMRI...
(Date:11/24/2009)...celand, November 24 deCO...that it has received notice from,the Nasdaq Stock ...will be,suspended as of November 30, 2009 and a Fo...change Commission, which will remove deCODE,s comm...y files an appeal to the Nasdaq,Listing Qualificat...
(Date:11/24/2009)...4 NeurogesX, Inc. (Nasda... developing and commercializing novel pain managem...o, President and Chief Executive Officer, is sched...ealth Care Conference, to be held December 1-2, 20...ork. ,, Mr. DiTonno and Stephen Ghiglieri, Chi...
Breaking Biology Technology:Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
... demand for a hydroponics file cabinet, Dealzer.co...and Mini-File hydroponic grow box systems. These s...consumers nationwide. , N...eased demand for a hydroponics file cabinet, Dealz...File and Mini-File hydroponic grow box systems. Th...
... Inc. (Nasdaq: AMLN ) issued the following state...astbourne Capital Management, L.L.C., made public ... consultation with numerous shareholders, Amylin h...urne and Carl Icahn which is in the best interests...main open to new ideas and perspectives. , , Foll...
...etics,(Nasdaq: DCGN ) today announced that its CL...ory, which processes the company,s deCODEme(TM) pe... tests for several common,diseases, has been accre...),following a recent inspection. The U.S. Centers ...ed the CAP Laboratory Accreditation Program deemin...
Other Biology Technology:Dealzer Hydroponics Introduces the Super-File Cabinet Grow Box System 2Amylin Responds to Eastbourne Letter 2Amylin Responds to Eastbourne Letter 3Amylin Responds to Eastbourne Letter 4deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 3deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 4
(Date:11/24/2009)...tutes fish food is a matter of debate. A high-prof...almost 50 percent of their carbon from trees and l...terrestrial and aquatic ecosystems. , But new re...s is not likely to be true. Algae provide a much r...ing to research published this week in the Procee...
(Date:11/23/2009)...D.C. The community-associated strain of the deadl...tant to most common antibioticsposes a far greater... its way into hospitals, according to a study in t... . , The new threat is easily picked up in fitn...has increased the overall burden of MRSA within ho...
(Date:11/23/2009)...f. -- More than 160 participants gathered this wee...UTURES INITIATIVE conference. This year,s topic, "...ngineers, and medical researchers to explore the e...ing the emerging field of synthetic biology. , B...t Princeton University and this year,s conference ...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2New Study Showed Lantus 28R 29 Plus One Two or Three Shots of Apidra 28R 29 Lowered Patients Blood Sugar 4547 1New Study Showed Lantus 28R 29 Plus One Two or Three Shots of Apidra 28R 29 Lowered Patients Blood Sugar 4547 2New Study Showed Lantus 28R 29 Plus One Two or Three Shots of Apidra 28R 29 Lowered Patients Blood Sugar 4547 3Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary En 4544 1Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary En 4544 2Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary En 4544 3Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary En 4544 4Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary En 4544 5Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary En 4544 6Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary En 4544 7Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary En 4544 8Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary En 4544 9Had Your Eyes Checked Lately 3F 48103 1Had Your Eyes Checked Lately 3F 48103 2Had Your Eyes Checked Lately 3F 48103 3
...BRIDGE, Mass As astronomers become more adept at ... stars, its natural to wonder if anybody is lookin... professor from MIT has figured out just what thos...veloped by Earths astronomers. , According to the...y tell that our planets surface is divided between...
... YORK (Dec. 20, 2007) -- At its core, healthy neur...of information between brain cells via the synapse...formation -- a process called neurotransmission --...ealthy and diseased brain. , Now, a team led by ...w York City has spotted a crucial new piece to tha...
...s book focuses on: , , The evolution of hydroecol...ological interactions, dynamics and linkages , Met...uture research needs , , The book considers a ran...provides a long-term perspective on contemporary a...plications with respect to environmental and water...
Other Biology News:MIT, others ask 'What would E.T. see?' 2MIT, others ask 'What would E.T. see?' 3A key enzyme helps keep the synapse on track 2A key enzyme helps keep the synapse on track 3
...m 2300 camera (MC2300) attaches to virtually any m...ular port. Included in the standard package, Motic...offers quick and accurate image capture, with Imag...amination or documentation purposes. The MC2300s U...
...aqueous solution that contains a purified bovine p...er (phosphate buffered saline), pH 7.0 7.4. This...oat Immunoassay Stabilizer preserves the conformat...munoassays and can be used as a coating or lyophil...
Mouse Anti-Human PARK2 Monoclonal Antibody, Unconjugated, Clone 1H4 from Novus Biologicals
Rabbit Anti-NMDA NR2B, phospho (Tyr1336) Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: